AmeRuss's leadership team is expertly familiar with all sides of a clinical trial. Collectively, they have more than eighty years of experience as clinical investigators, pharmaceutical consultants, statisticians and CRAs and are well connected within the pharmaceutical and medical industries worldwide. AmeRuss managing partners include three physician investigators who together have completed more than 450 clinical trials. Their expertise translates across borders as key leadership team members continue to reside and work within Russia and the European Union.
Paul Caldron
President and CEO
Paul Caldron, DO, FACP, FACR, MBA is a United States trained physician certified in internal medicine, rheumatology and geriatric medicine and is former CEO of the largest rheumatology group in the southwestern United States. He has been principal or sub-investigator on numerous pharmaceutical trials in the field of rheumatology. Dr. Caldron completed business training for an MBA degree at the top ranked Thunderbird School of Global Management in Arizona, USA.
Recent Publications:
Levy RM, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kantemirova
R, Mazurov V, Bell M, Caldron P, Pillai L, Burnett BP. Efficacy and safety of
flavocoxid, a novel therapeutic, compared with naproxen: a randomized
multicenter controlled trial in subjects with osteoarthritis of the knee.
Adv Ther. 27(10):731-742, 2010.
Tesser JR, Ballehr L, Jay R, Keske B, Konya M, Brown S, Caldron
P, Starr J, Peters E, Bennett R, Swarup A, Jajoo R, Bolignese J, Chhaya S,
D’Onofrio M. MRI RAMRIS Scores in Rheumatoid Arthritis: Experience in a Large
Community Based Rheumatology Practice. Arthritis Rheum 56(suppl 9):S653, 2007.
Barry S. Skikne, Kari Punnonen, Paul H. Caldron, Michael T.
Bennett, Mari Ervasti, Gail H. Gasior, Janna S. Chamberlin, Linda
A. Sullivan, Kurtis R. Bray, Paula C. Southwick. Improved differential
diagnosis of anemia of chronic disease and iron deficiency
anemia: A prospective multicenter evaluation of soluble transferrin
receptor (sTfR) and the sTfR / log ferritin index (sTfR Index). American
Journal of Hematology (accepted, publication date pending)
Paul H. Caldron, Igor Tartakovsky. Russians Mourn Iconic
Rheumatologist: Valentina A. Nasonova, MD, was Renaissance figure in Russian
rheumatology. The Rheumatologist, May 2011. 14-16.
John Tesser
Vice President, Business Development
John Tesser, MD, FACP, FACR is a United States trained physician certified in internal medicine and rheumatology who has been principal investigator in more than 250 clinical trials in multiple medical disciplines through past work with Radiant Research. Dr. Tesser has served as a consultant for numerous United States and European Union based pharmaceutical companies.
>
Recent Publications:
Tugwell P, Pincus T, Yocum D, Stein M,
Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G: Combination Therapy
with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis. N Engl J Med
333:137-41, 1995.
Genovese MC, Bathon JM, Martin RW,
Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW,
Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Etanercept versus
methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum
46(6):1443-50, 2002.
Tesser J, Fleischmann R, Dore R, et. Al.
Concomitant medication use in a large international multicenter placebo
controlled trial of Anakinra, a recombinant IL-1 receptor antagonist, in
patients with RA. J Rheumatol 31(4)649-654, 2004.
Furst DE, Halbert RJ, Bingham CO,
Fukudome S, Anderson L, Bonafede P, Bray V, Cohen SB, Sherrer YRS, St. Clair
EWS, Tesser JRP, Weinblatt M, Dubois RW. Evaluating the adequacy of disease
control in patients with rheumatoid arthritis: a RAND appropriateness panel.
Rheumatology. 47:194-199, 2008.
Pavel Shafranovskiy
Vice President, Corporate Development
Pavel Shafranovskiy, PhD, MBA holds a doctorate in chemical physics in Russia and business master's from the Open University of the United Kingdom, and is a principal shareholder in the SHAG Company. ZAO SHAG maintains eight distribution offices and 48 representatives in Russia for pharmaceuticals and durable medical products. Dr. Shafranovskiy is also a major shareholder in the Implanta Group of companies focused on the distribution of cardiovascular implantable devices. Dr. Shafranovskiy maintains close working relationships with national thought leaders and health system directors throughout the regions.
Andrei Bazarov
Medical Director, Acting Country Manager, Russia/CIS/NIS
Andrei Bazarov, MD, is currently Medical Director for AmeRuss and Acting Country Manager overseeing Russia, Belarus, and Ukraine. Dr. Bazarov holds a medical degree in Surgery (Russian State Medical University, Moscow). He took part as a Sub-investigator and Principal Investigator in numerous clinical studies in various fields of medicine especially surgical infections and sepsis, oncology, and vascular surgery. He is the past Executive Secretary of Surgical Infection Association of Russia (SIA-R), Secretary of the Moscow branch of Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC). He is currently and has been a member of Surgical Infection Society of North America (SIS-NA), the All-Russian Scientific Medical Society of Surgeons, the Russian Oncology Society, Ethics Committee of Burdenko Main Military Clinical Hospital. Dr. Bazarov is organizer and an active trainer and speaker on ICH GCP trainings, workshops, and seminars, and consultant on the Russian and CIS countries national legislations in the field of clinical trials.
